US · GMED
Globus Medical, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Audubon, PA 19403
- Website
- globusmedical.com
Price · as of 2025-12-31
$91.34
Market cap 12.89B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $105.89 | +15.93% |
| Intrinsic Value(DCF) | $168.01 | +83.94% |
| Graham-Dodd Method(GD) | $43.12 | -52.79% |
| Graham Formula(GF) | $95.56 | +4.61% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $7.93 | $18.80 | |||
| 2012 | $14.90 | $46.09 | $33.24 | $8.26 | $19.62 |
| 2013 | $25.30 | $44.61 | $21.71 | $8.60 | $14.95 |
| 2014 | $24.89 | $45.48 | $15.22 | $10.56 | $16.62 |
| 2015 | $25.51 | $44.90 | $21.55 | $12.49 | $26.45 |
| 2016 | $27.33 | $44.58 | $4.42 | $13.05 | $12.63 |
| 2017 | $51.28 | $59.75 | $9.26 | $14.35 | $22.73 |
| 2018 | $46.24 | $63.20 | $8.85 | $18.84 | $31.65 |
| 2019 | $42.76 | $62.20 | $6.69 | $20.67 | $28.00 |
| 2020 | $62.44 | $65.01 | $1.00 | $18.88 | $8.83 |
| 2021 | $68.61 | $73.07 | $5.83 | $22.91 | $42.36 |
| 2022 | $54.51 | $69.21 | $0.98 | $25.88 | $27.70 |
| 2023 | $55.36 | $63.20 | $25.47 | $28.10 | $64.33 |
| 2024 | $77.41 | $74.00 | $142.30 | $24.02 | $50.15 |
| 2025 | $93.80 | $105.89 | $315.86 | $43.12 | $95.56 |
AI valuation
Our deep-learning model estimates Globus Medical, Inc.'s (GMED) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $105.89
- Current price
- $91.34
- AI upside
- +15.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$168.01
+83.94% upside
Graham-Dodd
$43.12
-52.79% upside
Graham Formula
$95.56
+4.61% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GMED | Globus Medical, Inc. | $91.34 | 12.89B | +16% | +84% | -53% | +5% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| GRFS | Grifols, S.A. | $9.10 | 7.7B | +209% | -64% | — | -49% | 10.85 | 0.82 | 0.67 | 9.37 | 6.98 | -1.08 | 38.75% | 16.53% | 2.18% | 7.89% | 3.72% | 2.09% | 1.71 | 1.54 | 2.66 | 0.96 | 6.13 | 15556.00% | 941.00% | -67929.00% | 11.02% | 0.42 | 3.46% | 0.02% | 0.20% | 28.68% | 11.66 | 26.19 | 1.93 | 0.96 |
| HQY | HealthEquity, Inc. | $76.49 | 6.61B | -8% | -56% | -86% | -60% | 73.84 | 3.38 | 5.95 | 23.56 | 105.02 | -9.68 | 57.73% | 19.18% | 8.06% | 4.66% | 6.98% | 2.92% | 0.52 | 3.79 | 3.06 | 2.65 | 2.41 | 7031.00% | 2003.00% | 7167.00% | 4.73% | 2.17 | 12.30% | 0.00% | 0.00% | 1.70% | 34.57 | 23.55 | 6.63 | 3.98 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MOH | Molina Healthcare, Inc. | $154.05 | 7.93B | +43% | +423% | -46% | +17% | 16.40 | 1.90 | 0.17 | 7.63 | — | 4.13 | 8.97% | 1.72% | 1.04% | 11.02% | 52.20% | 3.03% | 0.97 | 4.07 | 1.69 | 1.06 | -0.31 | -5632.00% | 1175.00% | -21691.00% | -8.21% | -0.07 | -53.04% | 0.00% | 0.00% | 12.92% | 9.53 | -11.70 | 0.16 | 4.20 |
| PEN | Penumbra, Inc. | $344.39 | 13.51B | -36% | -28% | -84% | -67% | 74.97 | 9.33 | 9.49 | 59.99 | 6.49 | 10.62 | 67.14% | 13.48% | 12.66% | 13.78% | 13.14% | 10.58% | 0.15 | — | 6.64 | 2.06 | 0.15 | 115556.00% | 1750.00% | 1876.00% | 1.31% | 1.30 | 14.03% | 0.00% | 0.00% | 0.00% | 70.57 | 76.34 | 9.51 | 22.01 |
About Globus Medical, Inc.
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
- CEO
- Keith W. Pfeil
- Employees
- 5.3K
- Beta
- 1.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($168.01 ÷ $91.34) − 1 = +83.94% (DCF, example).